Neurology News and Research

Latest Neurology News and Research

RSAM, Rettsyndrome.org renew commitment to jointly defeat Rett syndrome

The Rett Syndrome Association of Massachusetts and Rettsyndrome.org announce today their renewed commitment to work together to defeat Rett syndrome. A generous $85,000 donation from RSAM will support an ongoing clinical trial for Rettsyndrome.org at Boston Children's Hospital.

13 Aug 2015

Regular exercise benefits children with multiple sclerosis

A new study suggests children with multiple sclerosis (MS) who exercise regularly may have a less active disease. The research is published in the August 12, 2015, online issue of Neurology, the medical journal of the American Academy of Neurology.

13 Aug 2015

Amyloid-beta kinetics reveal link between aging and AD risk

Slowed amyloid-beta turnover may explain aging’s association with increased amyloidosis and Alzheimer’s disease, say researchers.

12 Aug 2015

FDA accepts sNDA to review Brintellix clinical trial data for treatment of major depressive disorder

Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) announced today the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for review to add clinical data regarding the effect of Brintellix (vortioxetine) on certain aspects of cognitive function in adults with Major Depressive Disorder (MDD) to the current product label.

11 Aug 2015

Researchers identify first gene that causes common form of mitral valve prolapse

An international research collaboration led by Massachusetts General Hospital investigators has identified the first gene in which mutations cause the common form of mitral valve prolapse (MVP), a heart valve disorder that affects almost 2.5 percent of the population.

11 Aug 2015

Mallinckrodt subsidiary to acquire Therakos for $1.325 billion

Mallinckrodt plc, a leading specialty biopharmaceutical company, and The Gores Group, a global investment firm, announced today that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt will acquire Therakos, Inc. a leading immunotherapy company in a transaction valued at approximately $1.325 billion.

10 Aug 2015

Constraint-induced movement therapy trialled in patients’ homes

A randomised trial from Germany has attempted to turn constraint-induced movement therapy into a cost-effective home-based treatment for stroke survivors.

7 Aug 2015

Modern living could lead to 'hidden' epidemic of neurological brain disease

Modern living could be responsible for an 'almost epidemic' increase in neurological brain disease, according to new research from Bournemouth University.

6 Aug 2015

Structural brain changes found in chemoradiation-treated glioblastoma patients

US researchers find evidence of marked and progressive brain atrophy during standard chemoradiation therapy in patients with glioblastoma.

5 Aug 2015

Poor relapse recovery heralds progressive MS

Multiple sclerosis patients with poor recovery from relapses develop the progressive form faster than those with good recovery, research shows.

5 Aug 2015

Chronic inflammatory demyelinating polyneuropathy commonly misdiagnosed

Half of patients referred to a specialist centre with a diagnosis of chronic inflammatory demyelinating polyneuropathy do not actually have the condition, report researchers.

5 Aug 2015

Diaphragmatic pacing ’harmful’ in amyotrophic lateral sclerosis

Diaphragmatic pacing in conjunction with non-invasive ventilation is detrimental to patients with amyotrophic lateral sclerosis and respiratory insufficiency, show findings from a randomised controlled trial.

5 Aug 2015

MSK and LVHN collaborate to improve patients’ access to innovative cancer treatments

Memorial Sloan Kettering Cancer Center (MSK) and Lehigh Valley Health Network (LVHN) announced today the beginning of a unique and forward-thinking collaboration aimed at improving patient access to the latest and most effective cancer treatment advances and highest-caliber cancer care.

5 Aug 2015

Antiepileptic monotherapy does not increase intrauterine death risk

Neither type nor dosage of antiepileptic drug affects the risk of intrauterine death among pregnant women with epilepsy when given as monotherapy, suggests research.

4 Aug 2015

Gastrostomy methods equivalent in amyotrophic lateral sclerosis

The ProGas study results show that three methods of gastrostomy are equally good in terms of complications and survival in patients with amyotrophic lateral sclerosis.

4 Aug 2015

Cryptogenic stroke frequent and recurrent

Cryptogenic ischaemic strokes and transient ischaemic attacks frequently recur, despite having no identifiable cause, show findings from the Oxford Vascular Study.

4 Aug 2015

DBS may aid cortical plasticity in Parkinson’s patients

Deep-brain stimulation of the subthalamic nucleus may help to restore long-term potentiation-like plasticity in the motor cortex of patients with Parkinson’s disease, a study shows.

4 Aug 2015

Research finding could help reveal how the human brain learns complex motor skills

Like top musicians, songbirds train from a young age to weed out errors and trim variability from their songs, ultimately becoming consistent and reliable performers. But as with human musicians, even the best are not machines. To learn and improve, the songbird brain needs to shake up its tried-and-true patterns with a healthy dose of creative experimentation. Until now, no one has found a specific mechanism by which this could occur.

4 Aug 2015

Researchers uncover strong evidence for genetic causes of cerebral palsy

Cerebral palsy (CP) is the most common cause of physical disability in children. It has historically been considered to be caused by factors such as birth asphyxia, stroke and infections in the developing brain of babies.

3 Aug 2015

Eisai, Halozyme partner to evaluate eribulin and PEGPH20 in HER2-negative metastatic breast cancer

Eisai Inc. announced today that its parent company Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) and Halozyme Therapeutics, Inc. (Headquarters: San Diego, California, President and CEO: Dr. Helen Torley) have signed a clinical collaboration agreement to evaluate Eisai's agent eribulin mesylate (brand name: Halaven, "eribulin") in combination with Halozyme's investigational drug PEGPH20 (PEGylated recombinant human hyaluronidase) in first line HER2-negative metastatic breast cancer.

31 Jul 2015